Test Bank for Saunders Comprehensive Review for the NCLEX-
RN® Examination, 9th Edition by Linda Anne Silvestri and
Angela Silvestri Complete Questions and Answers Pass
Guaranteed
•
, Pharmacology
Test |Bank
|
MULTIPLE |CHOICE
1. The |nurse |is |caring |for |a |client |in |labor. |The |nurse |reviews |the |physician’s |prescriptions |and |notes |that |the
|client |has |a |prescription |for |butorphanol |tartrate |(Stadol). |The |nurse |understands |that |this |medication |is
|prescribed |for:
1. Pain |relief
2. Increasing |uterine |contractions
3. Decreasing |uterine |contractions
4. Promoting |fetal |lung |maturity
ANS: | | 1
Rationale: |The |client |in |labor |may |be |given |parenteral |analgesia |during |the |first |stage |of |labor, |up |to |2 |to |3
|hours |before |the |anticipated |delivery. |Butorphanol |tartrate |is |a |medication |that |may |be |prescribed |for |pain
|relief. |“Increasing |uterine |contractions,” |“decreasing |uterine |contractions,” |and |“promoting |fetal |lung
|maturity” |are |not |actions |of |this |medication.
Test-Taking |Strategy: |Knowledge |of |the |action |of |butorphanol |tartrate |is |required |to |answer |this |question.
|Remember |that |this |medication |is |used |for |pain |relief. |Review |the |action |of |this |medication |if |you |had
|difficulty |with |this |question |and |are |unfamiliar |with |this |medication.
PTS: 1
DIF: Level |of |Cognitive |Ability: |Understanding
REF: Lehne, |R. |(2010). |Pharmacology |for |nursing |care |(7th |ed.). |St. |Louis: |Saunders.
|OBJ: Client |Needs: |Physiological |Integrity
TOP: Content |Area: |Pharmacology
MSC: | Integrated |Process: |Nursing |Process—Planning
2. The |postpartum |nurse |is |caring |for |a |client |with |an |epidural |catheter |in |place |for |opioid |analgesic
|administration |following |cesarean |birth. |If |the |client |develops |respiratory |depression |and |requires
|naloxone |(Narcan) |as |an |antidote, |the |client |may |complain |of |which |of |the |following?
1. Increase |in |her |pain |level
2. Decrease |in |her |pain |level
3. Increase |in |the |amount |of |itching |from |the |opioid |used |in |the |epidural
4. Decrease |in |the |amount |of |itching |from |the |opioid |used |in |the |epidural
, ANS: | | 1
Rationale: |Remember |that |opioids |are |used |for |epidural |analgesia. |Naloxone |is |an |opioid |antagonist,
|which |reverses |the |effects |of |opioids. |If |it |is |given, |the |client |may |complain |of |an |increase |in |her |pain |level.
|Therefore |“decrease |in |her |pain |level,” |“increase |in |the |amount |of |itching |from |the |opioid |used |in |the
|epidural,” |and |“decrease |in |the |amount |of |itching |from |the |opioid |used |in |the |epidural” |are |incorrect.
Test-Taking |Strategy: |To |answer |this |question |accurately, |you |must |know |that |opioid |analgesics |are |the
|medications |used |with |epidural |analgesia |to |relieve |pain. |Therefore |if |naloxone |is |administered |as |an
|antidote |for |an |opioid |analgesic, |the |client’s |pain |will |increase. |Review |the |effects |of |naloxone |if |this
|question |was |difficult.
PTS: 1
DIF: Level |of |Cognitive |Ability: |Understanding
REF: Lehne, |R. |(2010). |Pharmacology |for |nursing |care |(7th |ed.). |St. |Louis: |Saunders.
|OBJ: Client |Needs: |Physiological |Integrity
TOP: Content |Area: |Pharmacology
MSC: | Integrated |Process: |Nursing |Process—Assessment
3. A |client |experiencing |preterm |labor |at |the |twenty-ninth |week |of |gestation |has |been |admitted |to |the
|hospital. |The |client |has |a |prescription |to |receive |betamethasone |(Celestone). |The |nurse |understands |that
|the |medication |will |do |which |of |the |following?
1. Prevent |spontaneous |delivery.
2. Stop |the |uterine |contractions.
3. Promote |maturation |of |the |fetal |lungs.
4. Accelerate |the |growth |rate |of |the |fetus.
ANS: | | 3
Rationale: |Betamethasone |(Celestone) |is |classified |as |an |anti-inflammatory |and |corticosteroid. |It
|increases |the |surfactant |level |and |lung |maturity |in |the |fetus, |which |reduces |the |incidence |of |respiratory
|distress |syndrome. |Delivery |must |be |delayed |for |at |least |48 |hours |after |administration |of |betamethasone |to
|allow |time |for |the |lungs |of |the |fetus |to |mature.
Test-Taking |Strategy: |Options |that |are |comparable |or |alike |are |not |likely |to |be |correct. |With |this |in |mind,
|eliminate |“prevent |spontaneous |delivery” |and |“stop |the |uterine |contractions.” |Note |the |strategic |words
|“twenty-ninth |week |of |gestation.” |Specific |knowledge |about |the |medication |and |knowledge |of |the
|problems |encountered |by |premature |infants |will |assist |in |answering |this |question. |Review |the |action |of
|this |medication |if |this |question |was |difficult.
PTS: 1
DIF: Level |of |Cognitive |Ability: |Understanding
REF: McKinney, |E., |James, |S., |Murray, |S., |& |Ashwill, |J. |(2009). |Maternal-child |nursing |(3rd |ed.). |St.
|Louis: |Saunders. OBJ: Client |Needs: |Physiological |Integrity
, TOP: Content |Area: |Pharmacology
MSC: | Integrated |Process: |Nursing |Process—Planning
4. A |client |with |preeclampsia |is |receiving |magnesium |sulfate. |The |nurse |assesses |the |client |closely |for
|which |sign |of |magnesium |toxicity?
1. Proteinuria
2. Hyperactive |deep |tendon |reflexes
3. Respiratory |rate |of |10 |breaths/min
4. Serum |magnesium |level |of |5 |mEq/L
ANS: | | 3
Rationale: |Magnesium |toxicity |is |a |risk |associated |with |magnesium |sulfate |therapy. |Signs |of |magnesium
|toxicity |relate |to |central |nervous |system |(CNS) |depression |and |include |respiratory |depression, |loss |of |deep
|tendon |reflexes, |and |sudden |drop |in |fetal |heart |rate |and/or |maternal |heart |rate |and |blood |pressure.
Magnesium |is |excreted |through |the |kidneys. |If |renal |impairment |is |present, |magnesium |toxicity |can |develop
|very |quickly. |Therapeutic |serum |levels |of |magnesium |are |4 |to |7 |mEq/L.
Test-Taking |Strategy: |To |answer |this |question |accurately, |you |must |recall |that |magnesium |sulfate |is |a
|CNS |depressant. |Begin |to |answer |this |question |by |eliminating |“proteinuria” |and |“hyperactive |deep |tendon
|reflexes,” |which |are |signs |of |preeclampsia. |Select |between |the |last |two |options |using |medication
|knowledge |and |recalling |that |the |therapeutic |serum |levels |of |magnesium |are |4 |to |7 |mEq/L. |Review |this
|medication |and |the |normal |magnesium |level |if |this |question |was |difficult.
PTS: 1
DIF: Level |of |Cognitive |Ability: |Analyzing
REF: Lowdermilk, |D., |Perry, |S., |& |Cashion, |K. |(2010). |Maternity |nursing |(8th |ed.). |St. |Louis: |Mosby.
OBJ: Client |Needs: |Physiological |Integrity
|TOP: Content |Area: |Pharmacology
MSC: | Integrated |Process: |Nursing |Process—Assessment
5. A |pregnant |client |who |has |human |immunodeficiency |virus |(HIV) |infection |is |being |seen |in |the |antenatal
|clinic. |The |nurse |recalls |that |zidovudine |(AZT) |therapy |will |be |initiated |when |the |fetus |has |reached |how
|many |weeks |of |gestation?
1. 4
2. 14
3. 24
4. 34
ANS: | | 2
Rationale: |The |pregnant |women |with |HIV |infection |will |be |prescribed |oral |AZT |in |the |fourteenth |week |of
|gestation. |Before |this |time, |the |fetus |is |at |risk |because |of |the |teratogenic |effects |of |the |medication. |In
RN® Examination, 9th Edition by Linda Anne Silvestri and
Angela Silvestri Complete Questions and Answers Pass
Guaranteed
•
, Pharmacology
Test |Bank
|
MULTIPLE |CHOICE
1. The |nurse |is |caring |for |a |client |in |labor. |The |nurse |reviews |the |physician’s |prescriptions |and |notes |that |the
|client |has |a |prescription |for |butorphanol |tartrate |(Stadol). |The |nurse |understands |that |this |medication |is
|prescribed |for:
1. Pain |relief
2. Increasing |uterine |contractions
3. Decreasing |uterine |contractions
4. Promoting |fetal |lung |maturity
ANS: | | 1
Rationale: |The |client |in |labor |may |be |given |parenteral |analgesia |during |the |first |stage |of |labor, |up |to |2 |to |3
|hours |before |the |anticipated |delivery. |Butorphanol |tartrate |is |a |medication |that |may |be |prescribed |for |pain
|relief. |“Increasing |uterine |contractions,” |“decreasing |uterine |contractions,” |and |“promoting |fetal |lung
|maturity” |are |not |actions |of |this |medication.
Test-Taking |Strategy: |Knowledge |of |the |action |of |butorphanol |tartrate |is |required |to |answer |this |question.
|Remember |that |this |medication |is |used |for |pain |relief. |Review |the |action |of |this |medication |if |you |had
|difficulty |with |this |question |and |are |unfamiliar |with |this |medication.
PTS: 1
DIF: Level |of |Cognitive |Ability: |Understanding
REF: Lehne, |R. |(2010). |Pharmacology |for |nursing |care |(7th |ed.). |St. |Louis: |Saunders.
|OBJ: Client |Needs: |Physiological |Integrity
TOP: Content |Area: |Pharmacology
MSC: | Integrated |Process: |Nursing |Process—Planning
2. The |postpartum |nurse |is |caring |for |a |client |with |an |epidural |catheter |in |place |for |opioid |analgesic
|administration |following |cesarean |birth. |If |the |client |develops |respiratory |depression |and |requires
|naloxone |(Narcan) |as |an |antidote, |the |client |may |complain |of |which |of |the |following?
1. Increase |in |her |pain |level
2. Decrease |in |her |pain |level
3. Increase |in |the |amount |of |itching |from |the |opioid |used |in |the |epidural
4. Decrease |in |the |amount |of |itching |from |the |opioid |used |in |the |epidural
, ANS: | | 1
Rationale: |Remember |that |opioids |are |used |for |epidural |analgesia. |Naloxone |is |an |opioid |antagonist,
|which |reverses |the |effects |of |opioids. |If |it |is |given, |the |client |may |complain |of |an |increase |in |her |pain |level.
|Therefore |“decrease |in |her |pain |level,” |“increase |in |the |amount |of |itching |from |the |opioid |used |in |the
|epidural,” |and |“decrease |in |the |amount |of |itching |from |the |opioid |used |in |the |epidural” |are |incorrect.
Test-Taking |Strategy: |To |answer |this |question |accurately, |you |must |know |that |opioid |analgesics |are |the
|medications |used |with |epidural |analgesia |to |relieve |pain. |Therefore |if |naloxone |is |administered |as |an
|antidote |for |an |opioid |analgesic, |the |client’s |pain |will |increase. |Review |the |effects |of |naloxone |if |this
|question |was |difficult.
PTS: 1
DIF: Level |of |Cognitive |Ability: |Understanding
REF: Lehne, |R. |(2010). |Pharmacology |for |nursing |care |(7th |ed.). |St. |Louis: |Saunders.
|OBJ: Client |Needs: |Physiological |Integrity
TOP: Content |Area: |Pharmacology
MSC: | Integrated |Process: |Nursing |Process—Assessment
3. A |client |experiencing |preterm |labor |at |the |twenty-ninth |week |of |gestation |has |been |admitted |to |the
|hospital. |The |client |has |a |prescription |to |receive |betamethasone |(Celestone). |The |nurse |understands |that
|the |medication |will |do |which |of |the |following?
1. Prevent |spontaneous |delivery.
2. Stop |the |uterine |contractions.
3. Promote |maturation |of |the |fetal |lungs.
4. Accelerate |the |growth |rate |of |the |fetus.
ANS: | | 3
Rationale: |Betamethasone |(Celestone) |is |classified |as |an |anti-inflammatory |and |corticosteroid. |It
|increases |the |surfactant |level |and |lung |maturity |in |the |fetus, |which |reduces |the |incidence |of |respiratory
|distress |syndrome. |Delivery |must |be |delayed |for |at |least |48 |hours |after |administration |of |betamethasone |to
|allow |time |for |the |lungs |of |the |fetus |to |mature.
Test-Taking |Strategy: |Options |that |are |comparable |or |alike |are |not |likely |to |be |correct. |With |this |in |mind,
|eliminate |“prevent |spontaneous |delivery” |and |“stop |the |uterine |contractions.” |Note |the |strategic |words
|“twenty-ninth |week |of |gestation.” |Specific |knowledge |about |the |medication |and |knowledge |of |the
|problems |encountered |by |premature |infants |will |assist |in |answering |this |question. |Review |the |action |of
|this |medication |if |this |question |was |difficult.
PTS: 1
DIF: Level |of |Cognitive |Ability: |Understanding
REF: McKinney, |E., |James, |S., |Murray, |S., |& |Ashwill, |J. |(2009). |Maternal-child |nursing |(3rd |ed.). |St.
|Louis: |Saunders. OBJ: Client |Needs: |Physiological |Integrity
, TOP: Content |Area: |Pharmacology
MSC: | Integrated |Process: |Nursing |Process—Planning
4. A |client |with |preeclampsia |is |receiving |magnesium |sulfate. |The |nurse |assesses |the |client |closely |for
|which |sign |of |magnesium |toxicity?
1. Proteinuria
2. Hyperactive |deep |tendon |reflexes
3. Respiratory |rate |of |10 |breaths/min
4. Serum |magnesium |level |of |5 |mEq/L
ANS: | | 3
Rationale: |Magnesium |toxicity |is |a |risk |associated |with |magnesium |sulfate |therapy. |Signs |of |magnesium
|toxicity |relate |to |central |nervous |system |(CNS) |depression |and |include |respiratory |depression, |loss |of |deep
|tendon |reflexes, |and |sudden |drop |in |fetal |heart |rate |and/or |maternal |heart |rate |and |blood |pressure.
Magnesium |is |excreted |through |the |kidneys. |If |renal |impairment |is |present, |magnesium |toxicity |can |develop
|very |quickly. |Therapeutic |serum |levels |of |magnesium |are |4 |to |7 |mEq/L.
Test-Taking |Strategy: |To |answer |this |question |accurately, |you |must |recall |that |magnesium |sulfate |is |a
|CNS |depressant. |Begin |to |answer |this |question |by |eliminating |“proteinuria” |and |“hyperactive |deep |tendon
|reflexes,” |which |are |signs |of |preeclampsia. |Select |between |the |last |two |options |using |medication
|knowledge |and |recalling |that |the |therapeutic |serum |levels |of |magnesium |are |4 |to |7 |mEq/L. |Review |this
|medication |and |the |normal |magnesium |level |if |this |question |was |difficult.
PTS: 1
DIF: Level |of |Cognitive |Ability: |Analyzing
REF: Lowdermilk, |D., |Perry, |S., |& |Cashion, |K. |(2010). |Maternity |nursing |(8th |ed.). |St. |Louis: |Mosby.
OBJ: Client |Needs: |Physiological |Integrity
|TOP: Content |Area: |Pharmacology
MSC: | Integrated |Process: |Nursing |Process—Assessment
5. A |pregnant |client |who |has |human |immunodeficiency |virus |(HIV) |infection |is |being |seen |in |the |antenatal
|clinic. |The |nurse |recalls |that |zidovudine |(AZT) |therapy |will |be |initiated |when |the |fetus |has |reached |how
|many |weeks |of |gestation?
1. 4
2. 14
3. 24
4. 34
ANS: | | 2
Rationale: |The |pregnant |women |with |HIV |infection |will |be |prescribed |oral |AZT |in |the |fourteenth |week |of
|gestation. |Before |this |time, |the |fetus |is |at |risk |because |of |the |teratogenic |effects |of |the |medication. |In
